Involvement of a Rho‐ROCK‐JNK pathway in arsenic trioxide‐induced apoptosis in chronic myelogenous leukemia cells
- 14 December 2006
- journal article
- Published by Wiley in FEBS Letters
- Vol. 581 (1) , 118-124
- https://doi.org/10.1016/j.febslet.2006.12.016
Abstract
The apoptotic signals activated by As2O3 in the chronic myelogenous leukemia (CML) cell lines K562 and KCL22 were investigated. As2O3 was found to induce apoptosis in these cells via the intrinsic pathway. As2O3 also induced a sustained c-Jun NH2-terminal kinase (JNK) activation which preceded and was necessary for caspase-9 activation. We established that Rho and its effector, the kinase ROCK, are activated by As2O3. Inhibition of either Rho or ROCK prevented JNK activation and protected against apoptosis. Thus, in CML cells, apoptosis induced by As2O3 is mediated, at least in part, via a Rho-ROCK-JNK axis. These findings define a novel signaling pathway for As2O3-induced apoptosisKeywords
This publication has 35 references indexed in Scilit:
- Scaffold proteins dictate Rho GTPase-signaling specificityTrends in Biochemical Sciences, 2005
- Bax and Bak are required for cytochrome c release during arsenic trioxide-induced apoptosisCancer Biology & Therapy, 2005
- Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agentCurrent Medical Research and Opinion, 2005
- Arsenic trioxide (As2O3) induces apoptosis through activation of Bax in hematopoietic cellsOncogene, 2005
- Interaction of the tyrosine phosphatase SHP-2 with Gab2 regulates Rho-dependent activation of the c-fosserum response element by interleukin-2Biochemical Journal, 2004
- JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cellsBlood, 2004
- Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1Leukemia, 2003
- Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapyLeukemia, 2002
- Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous LeukemiaNew England Journal of Medicine, 2002
- RHO–GTPases and cancerNature Reviews Cancer, 2002